Multiparametric ultrasound in the detection of prostate cancer: a systematic review by Arnoud Postema et al.
1 3
World J Urol (2015) 33:1651–1659
DOI 10.1007/s00345-015-1523-6
INVITED REVIEW
Multiparametric ultrasound in the detection of prostate cancer:  
a systematic review
Arnoud Postema · Massimo Mischi · Jean de la Rosette · 
Hessel Wijkstra 
Received: 1 February 2015 / Accepted: 28 February 2015 / Published online: 12 March 2015 
© The Author(s) 2015. This article is published with open access at Springerlink.com
Introduction
The tools for the detection of prostate cancer (PCa) usu-
ally consist of digital rectal examination (DRE), serum 
prostate-specific antigen (PSA) measurement and greyscale 
TransRectal UltraSonography (TRUS). Since these investi-
gations are limited in terms of sensitivity and positive pre-
dictive value (PPV), the diagnosis needs to be confirmed 
using TRUS-guided systematic random biopsies [1]. The 
resulting sample error from these untargeted biopsies is 
cause of many negative biopsies, while significant tumours 
are missed or under-graded [2].
Clearly, diagnosis through systematic untargeted biop-
sies is far from ideal, and the lack of an adequate imag-
ing tool is a major deficit of the diagnostic pathway. Con-
sequently, research is prioritized towards finding imaging 
techniques that enable replacing systematic untargeted 
biopsies by a few targeted biopsies. When a sufficiently 
high negative predictive value (NPV) is attained, it should 
be possible to exclude PCa based on imaging alone, elimi-
nating the necessity of taking prostate biopsies in every 
patient with a suspicion based on DRE or PSA.
Research on PCa imaging has focussed on two plat-
forms: magnetic resonance imaging (MRI) and ultrasound. 
Different MRI modalities exist. Since one modality alone 
does not seem to have sufficient diagnostic accuracy, the 
current literature recommends combining them into mul-
tiparamteric MRI (mpMRI) [3].
For the ultrasound platform too, various modalities 
were developed. These include dynamic contrast-enhanced 
UltraSound (DCE-US), colour Doppler ultrasound (CDU), 
power Doppler ultrasound (PDU), computerized tran-
srectal ultrasound (C-TRUS) and elastography. Similar to 
the development of mpMRI, the usage of a combination 
of these ultrasound-based modalities, “multiparametric 
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UltraSound (mpUS)”, could potentially improve the diag-
nostic performance. This paper presents the basic princi-
ples and performance of different ultrasound-based modali-
ties and investigates the clinical results of combining them 
into mpUS.
Methods
A systematic literature search on mpUS was performed 
using the Medline database. The aim was finding origi-
nal articles concerning the detection of PCa with at 
least two advanced ultrasound modalities (Fig. 1). The 
exact search term was: “Prostate Cancer AND ((Dop-
pler AND Elastography OR (DCE-US OR CEUS OR 
Contrast ultrasound)) OR (Elastography AND (DCE-
US OR CEUS OR Contrast ultrasound))) NOT review 
[Publication Type]”. Additional filters were applied to 
exclude articles published over 10 years ago, animal 
studies, non-English texts and articles with unavail-
able full texts. The titles and abstracts of the remaining 
results were screened for relevance. After full-text eval-
uation, studies were selected that reported the in vivo 




Conventional transrectal greyscale ultrasound (GSU) is 
currently the standard imaging tool for the prostate [1]. 
GSU is used for volumetry, needle guidance for system-
atic biopsies and guiding seed placement in brachytherapy 
[4]. The sensitivity of GSU for prospective tumour detec-
tion—varying by experience—has been reported to be up 
to 60 %. This reflects known sonographic properties of 
PCa: approximately 60 % of tumours appear hypoecho-
genic [5]. Around 35–39 % of tumours are isoechogenic, 
limiting the detection potential of GSU [6, 7]. The perfor-
mance reported in the literature varies widely with sensi-
tivities ranging between 8 and 88 % and specificities rang-
ing from 42.5 to 99 % [8–13]. The three studies with the 
highest specificities report the lowest sensitivities, possibly 
reflecting conservative interpretation [11–13]. The PPV and 
Fig. 1  Flow chart. PCa prostate 
cancer, US ultrasound, NPV 
negative predictive value, PPV 
positive predictive value
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specificity suffer from the high number of false positives 
caused by processes such as prostatitis, benign prostate 
hyperplasia, atrophy and infarction that mimic the typical 
appearance of PCa [5].
Computer-analysed TRUS
Several systems for computerized analysis of GSU images 
have been developed that use various algorithms to pre-
dict whether tissue is malignant [14]. The first and so far 
best results in clinical testing have come from the artifi-
cial neural network/C-TRUS (ANNA/C-TRUS) system. In 
the current “network version” of the C-TRUS system, the 
static TRUS images are transmitted to the C-TRUS server 
by a secured web-based system respecting the protection 
of patient data. The C-TRUS system uses an ANNA algo-
rithm to analyse the ultrasound signals and highlight suspi-
cious areas on the images that are transmitted back to the 
user [15]. An external validation study comparing results 
from the current version of the C-TRUS system with radi-
cal prostatectomy (RP) specimens in 28 patients showed 
a sensitivity, specificity, PPV and NPV of 83, 64, 80 and 
63 %, respectively [16]. In the primary study that evaluated 
patients with up to 70 prior negative systematic biopsies, 
C-TRUS detected 66 cancers in 132 men in which the can-
cer was missed by 12 (median) systematic biopsies [17]. 
In a prospective study in 164 patients, C-TRUS/ANNA-
guided biopsies were compared to the final pathology of 
the RP specimen. ANNA/C-TRUS could preoperatively 
predict the RP Gleason grade of the index lesion in 85 % 
[18]. Larger, multicentre trials are underway to support the 
evidence published so far [19].
The initial results for a different quantification tech-
nique, histoscanning, were favourable. Two small studies 
comparing histoscanning with RP specimens comprising 
of nine and 27 patients showed sensitivities of 90–100 % 
and specificities of 72–82 % [19]. However, histoscanning 
could not accurately predict biopsy results in a cohort of 
198 men according to a sextant analysis [20]. Finally, a 
paper evaluated the ability of histoscanning to detect, char-
acterize and locally stage PCa by comparing it with TRUS-
guided prostate biopsies, transperineal template prostate 
biopsies (TTBs) and RP specimens in three separate stud-
ies [21]. In the comparison between histoscanning-targeted 
biopsies and standard TRUS-guided biopsies, the former 
had an overall cancer detection rate of 38.1 % and the latter 
of 62.5 %. In the comparison between the histoscanning-
targeted biopsies and standard TTB, the targeted biopsies 
had an overall cancer detection rate of 13.4 % compared 
to 54.4 % for standard TTB. No correlation between total 
tumour volume estimates from histoscanning and RP 
specimens was found, and the sensitivity and specificity 
to detect tumour volumes over 0.5 mL were 37 and 71 %, 
respectively. Histoscanning is, therefore, currently not rec-
ommended to reliably identify and characterize PCa.
Doppler/power Doppler
PCa requires angiogenesis to develop into clinically signifi-
cant disease [22]. The resultant increase in microvascular 
density (MVD) is associated with higher tumour grade and 
worse prognosis [22]. The increased perfusion in malignant 
tissue is targeted by Doppler ultrasound imaging. Colour 
Doppler ultrasound (CDU) depicts flow by exploiting the 
shift in frequency that occurs when the signal is reflected 
by blood cells that are moving away or towards the trans-
ducer [22]. Power Doppler ultrasound (PDU) is more 
sensitive but does not depict the direction of flow. PDU 
can detect flow in vessels as small as 1 mm and therefore 
allows visualization of a tumour’s feeding vessels. How-
ever, the true angiogenic microvessels are in the 10–50 μM 
range [22].
Various authors reported additional value of the Doppler 
techniques over GSU [8, 10, 13]. In particular, two studies 
that reconstructed the vascularization in 3D with PDU per-
formed well [8, 12]. The largest study to date, by Eisenberg 
et al. [9], compared GSU and PDU with 620 RP specimens 
and reported that adding PDU to GSU improved specificity 
from 47 to 74 %, although the sensitivity decreased from 
58 to 47 %. Results vary greatly between studies, reflecting 
differences in study design, imaging protocols and popula-
tion. A meaningful additional benefit of these techniques 
compared to GSU within each study could not be univer-
sally demonstrated [23, 24]. As hypervascularity detected 
by Doppler ultrasound is not based on true angiogenic 
microvessels but on the larger feeding vessels, Doppler US 
is more sensitive to larger, higher Gleason grade lesions 
[10, 13].
Contrast-enhanced ultrasound
In contrast-enhanced ultrasound, an ultrasound contrast 
agent (UCA) consisting of gas-filled microbubbles is 
administered intravenously just prior to or during ultra-
sound imaging [25]. The microbubbles have diameters 
comparable to that of erythrocytes, enabling them to pass 
the microvasculature [22]. Contrast ultrasound has been 
used to evaluate perfusion of the heart and abdominal 
organs [26, 27].
The microbubbles were first used as additional reflectors 
in combination with the Doppler techniques, supposedly 
increasing sensitivity. Sedelaar et al. [28] first demonstrated 
that MVD, associated with PCa, was almost double in areas 
that presented contrast-enhanced power Doppler ultrasound 
(CE-PDU) enhancement compared to unenhanced prostate 
areas. They were able to find an average of 86 % of PCa’s 
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in 70 patients scheduled for RP using 3D CE-PDU [29]. A 
recent, large trial by Mitterberger et al. [30] comparing the 
detection rates of five contrast-enhanced colour Doppler 
ultrasound (CE-CDU)-targeted biopsies and ten systematic 
biopsies in 1776 men found a significantly higher positive 
core rate for the targeted biopsies compared to the system-
atic biopsies (11 vs 5 %). A smaller biopsy-based study by 
Taverna et al. [24] was not able to demonstrate a signifi-
cantly higher positive biopsy rate of CE-PDU compared to 
PDU or GSU.
In the past years, dynamic contrast-enhanced ultrasound 
(DCE-US) has emerged, using low-energy US pulses pre-
venting the premature bursting of the microbubbles [31]. 
This technique exploits the microbubbles’ nonlinear oscil-
lations in the ultrasound field, causing nonlinear reflections 
which can be discriminated from the linear tissue reflec-
tions [31]. This allows contrast-specific imaging, sensitive 
enough to detect a single microbubble and therefore visu-
alization of blood flow through the true microvasculature 
[32]. Several features are associated with malignancy: 
asymmetrical rapid inflow (enhancement), increased focal 
enhancement and asymmetry of intraprostatic vessels 
(Fig. 2) [33]. A limited number of studies have compared 
DCE-US imaging with RP specimens. Halpern et al. [34] 
and Matsumoto et al. [35] achieved sensitivities of 42 and 
41 % combining DCE-US and GSU in 12 and 50 patients, 
respectively. Unfortunately, their study design did not allow 
calculation of specificity. More recent studies are presented 
in Table 1. A yet unpublished study from our own institu-
tion compared the diagnostic performance parameters of 
Fig. 2  Multiparametric ultrasound and MRI modalities. Top left 
and right T2-MRI and diffusion-weighted MRI indicating tumour 
presence on the left side. Middle left and right GSU and elastogra-
phy indicating tumour presence on the left side. Bottom left and right 
DCE-US and pathology indicating tumour presence on both sides
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DCE-US and mpMRI in 36 patients using RP specimens 
as reference standard. For lesions 0.5 mL or larger, the two 
observers for DCE-US achieved a sensitivity of 58–69 % 
and a specificity of 93–95 % which was comparable to 
the performance of mpMRI under the same conditions. Qi 
et al. [36] were able to detect the index tumour in 67 of the 
83 patients they examined with DCE-US before RP. 
Recently, quantification techniques are being developed 
that extract blood flow parameters from DCE-US data that 
help predict whether tissue is malignant using different 
blood flow models. Quantitative maps of perfusion param-
eters can be generated by analysis of the time evolution of 
the UCA concentration [37]. The latest developments are, 
however, focussing on the assessment of the dispersion 
kinetics of the UCA passing through the microvasculature 
as a better indicator of microvascular architecture and high-
lighting those changes related to cancer neoangiogenesis 
[38–40]. Quantification is thought to be able to improve 
accuracy and decrease user dependency associated with 
DCE-US interpretation [32]. Still to be published data 
from our own institution showed that using dispersion-
based quantification increased sensitivity from 72 to 87 %, 
while specificity decreased from 92 to 84 % using 11 RP 
specimens as reference standard. Jung et al. [41] achieved 
a 88 % sensitivity and a 100 % specificity using DCE-US 
quantification in 20 patients scheduled for RP.
A major limitation in current DCE-US imaging is that 
recording the inflow and outflow takes about 2 min and 
only one plane can be recorded at a time. An interval of 
3–5 min between boluses is required to allow sufficient 
UCA breakdown to be able to evaluate contrast inflow. A 
major step will be the use of 3D endorectal probes suitable 
for DCE-US. This will allow repetitive 3D (or 4D) scan-
ning of UCA flow through the entire prostate after a sin-
gle bolus injection. Availability of ultrasound systems with 
DCE-US compatible endorectal probes is limited, and no 
data on 4D DCE-US are published yet.
Elastography
Most PCas are harder than normal prostatic tissue, which 
is the basis for PCa detection by DRE. This stiffening is 
caused by increased cellularity and microvascularity and 
a stromal response causing increased collagen deposition 
around the tumour [42]. Two variants of ultrasound elastog-
raphy exploit this difference in stiffness: the more exten-
sively evaluated quasi-static or strain elastography (SE) and 
the novel shear wave elastography (SWE).
Table 1  Overview of studies assessing diagnostic performance of transrectal ultrasound-based imaging modalities for the detection of prostate 
cancer
Performance parameters in percentages rounded to integers
GSU greyscale ultrasound, RP radical prostatectomy, C-TRUS computer-assisted transrectal ultrasound, DCE-US dynamic contrast-enhanced 
ultrasound, SE strain elastography, SWE shear wave elastography, 3D-PDU three-dimensional power Doppler ultrasound, RCP radical cysto-
prostatectomy, ROI region of interest, Sens. sensitivity, Spec. specificity, PPV positive predictive value, NPV negative predictive value, AMC 
Academic Medical Center, Amsterdam, The Netherlands
Modality Author Patients Design Sens. Spec. PPV NPV
GSU Sauvain [8] 282 GSU versus 6–8 biopsies 88 58 72 79
Eisenberg et al. [9] 620 GSU versus RP 59 47 91 11
Zalesky et al. [12] 146 GSU versus RP 8 99 83 59
Kuligowska et al. [10] 544 GSU versus 12 biopsies 41 85 53 72
C-TRUS Walz et al. [16] 28 C-TRUS versus RP 83 64 80 68
Loch et al. [18] 164 C-TRUS versus RP 82 80
Doppler Sauvain [8] 282 3D-PDU versus 6–8 biopsies 92 72 80 88
Kuligowska et al. [10] 544 CDU versus 12 biopsies 53 66 41 69
Eisenberg et al. [9] 620 PDU versus RP 40 35 88 6
Zalesky et al. [12] 146 3D-PDU versus RP 62 79 72 70
DCE-US Seitz et al. [33] 35 DCE-US versus RP and RCP 69 33 84 18
Unpublished data from AMC 36 DCE-US + GSU versus RP 58–69 93–95
Unpublished data from AMC 11 Semiquantative DCE-US + GSU versus RP 87 84
Jung et al. [41] 20 Semiquantitative DCE-US versus RP 88 100
SE Zhang et al. [44] 508 Meta-analysis of 7 studies: SE versus RP 72 76
Teng et al. [45] 527 Meta-analysis: SE-targeted biopsy versus systematic biopsy 62 79
SWE Ahmad et al. [49] 50 Per ROI SWE versus 12 biopsies 90–93 88–93 93–98 83–81
Barr et al. [48] 53 Per ROI SWE versus 12 biopsies 96 96 69 100
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In SE, cyclic compression is applied to the prostate using 
the endorectal probe, resulting in a changed morphology of 
the prostate tissues. Harder tissues are less affected than 
softer tissues, and this variation in the amount of deforma-
tion (strain) is displayed in the form of a colour overlay 
(Fig. 2) [43]. A recently published meta-analysis of seven 
studies comparing SE with RP specimens found a pooled 
sensitivity and specificity of 72 and 76 %, respectively 
[44]. A 2012 meta-analysis by Teng et al. [45] evaluating 
the accuracy of SE-targeted biopsies pooled the data of six 
studies to find a per-patient sensitivity of 62 %, specificity 
of 79 % and a per-core sensitivity and specificity of 34 and 
93 %, respectively. Both meta-analyses confirm that hetero-
geneity in study designs exists, making direct comparison 
of results difficult. Nevertheless, SE has shown consistently 
good results with a clear additional value to GSU. Several 
authors found that higher Gleason grade lesions were more 
easily detected by SE [13, 46]. The subjective interpreta-
tion of the colour maps and the free-hand cyclic compres-
sion of the prostate add considerable user dependency to 
SE imaging. Tsutsumi et al. [47] improved their SE results 
by using balloon inflation to exert force on the prostate 
rather than manual compression. A major drawback of SE 
is that the colour map is automatically scaled between the 
softest and the hardest tissue in the imaged field. It contains 
no absolute measure of elasticity, disabling quantification 
techniques and comparison of stiffness between patients 
[43].
SWE is a novel technique that assesses stiffness by 
measuring the velocity at which a shear wave travels 
through the tissues. The shear wave, induced within the 
tissue by using the acoustic radiation force produced by 
a focused ultrasound beam, propagates faster through 
stiffer tissue [48]. The speed of shear wave propagation 
is related to the Young’s modulus (the ratio of stress put 
on the tissue to the resulting deformation) and is dis-
played as a colour map [43]. Two clear advantages are 
that SWE does not require manual cyclic compression of 
the prostate and quantification is possible because shear 
wave velocity and Young’s modulus are absolute values. 
Only a limited amount data are available for SWE. Cor-
relating SWE imaging and sextant biopsy results in 53 
men, Barr et al. [48] achieved a sensitivity of 96 %, a 
specificity of 96 %, a PPV of 69 % and a NPV of almost 
100 %. Young’s modulus was significantly higher in areas 
with malignant tissue compared to areas with atypia or 
inflammation. In a study with a similar design among 50 
patients by Ahmad et al. [49], SWE reached sensitivi-
ties and specificities of 90 and 88 % in patients with a 
PSA value below 20 ng/mL and 93 and 93 % in patients 
with a PSA value above 20 ng/mL. Their data also sug-
gest a relationship between Young’s modulus and Glea-
son grade.
mpUS
The ultrasound modalities discussed here exploit differ-
ent physical characteristics of malignant tissue: GSU and 
C-TRUS visualize anatomical structures; the Doppler tech-
niques depict increased macrovascularity, DCE-US tar-
gets microvascularity, and elastography the increased stiff-
ness. Therefore, combining the modalities has the potential 
to detect more tumours while being more specific because 
more characteristics of suspicious lesions are evaluated 
(Fig. 2). Unfortunately, there are limited data on the perfor-
mance of combinations of ultrasound modalities. A study in 
133 patients by Aigner et al. [50] showed that a median of 
five biopsies targeted at SE and DCE-US lesions resulted in 
a higher per-patient detection rate (59.4 %) than what can be 
expected of systematic biopsies. Unfortunately, their study 
design does not allow calculation of false negatives. The 
systematic literature search identified two additional studies 
using systematic biopsy as a reference standard and only one 
study correlating mpUS with RP specimens (Fig. 1). Nelson 
et al. [13] compared GSU, PDU and SE in 137 patients using 
targeted biopsies with sextant systematic biopsies as refer-
ence standard. Of the 106 positive biopsy sites, GSU was 
positive in 16 %, CDU in 29 %, SE in 25 % and the combi-
nation in 46 %, showing that the three modalities detect dif-
ferent tumours. Xie et al. [51] compared the results of a 10 
core biopsy scheme with GSU, PDU and DCE-US imaging 
in 150 patients. GSU was positive in 51 % of cancer sites, 
PDU in 48 % and DCE-US in 73 %, while the combination 
was positive in 82 % of cancer sites. Both studies combine 
the ultrasound modalities by adding up all lesions seen by 
any of the modalities. This by default increases sensitivity 
and NPV at the cost of specificity and PPV. Unfortunately, 
insufficient data were supplied in the articles to calculate 
specificity for the combinations. Conversely, other authors 
combine ultrasound modalities by using the second modal-
ity to further characterize lesions highlighted by the first. 
This will produce a higher specificity and PPV at the cost 
of sensitivity and NPV. Brock et al. [52] compared SE and 
DCE-US with 100 RP specimens. Prostates were scanned 
with SE, resulting in a sensitivity of 49 % and a specificity 
of 74 %. Eighty-six target lesions were defined by SE and 
further characterized by DCE-US. This way the PPV of the 
target lesions increased from 65 % for SE alone to 90 % for 
the combination of SE and DCE-US.
A clinically more valuable balance between sensitivity 
and specificity or NPV and PPV can be obtained by the 
methods described above. When cancer detection is consid-
ered paramount, additional ultrasound modalities pinpoint-
ing more suspicious areas for targeted biopsy might prove 
usable if the combined NPV is high and the number of tar-
geted biopsies workable. The studies by Nelson et al. and 
Xie et al. show that a 13–59 % increase in sensitivity can be 
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achieved by combining the better performing modality with 
a second lower performing modality in a crude fashion. A 
potentially better system for combining imaging modalities 
would be a scoring system analogous to the mpMRI’s PI-
RADS. This system uses Likert-type scales for each modal-
ity and a total score representing the chance of cancer pres-
ence for that region [53]. However, a more sophisticated 
classifier algorithm, fully exploiting and integrating the 
complementary qualities of the different imaging modali-
ties, could be constructed based on, for example, a support 
vector machine or an artificial neural network [54]. This 
would allow incorporation of human interpreted imaging 
data on Likert-type scales, unstratified quantification data 
and even patient characteristics. Ideally, the output of such 
an algorithm should differentiate between high-risk and 
low-risk disease. Prerequisites for the development of such 
an advanced mpUS system are the acquisition of data in 
large patient cohorts using standardized imaging protocols.
Discussion
This review shows that promising results can be achieved by 
ultrasound-based imaging (Table 1). Sensitivities approach 
many of those reported for mpMRI and surpass those of the 
individual modalities that constitute mpMRI [55–58]. Our 
literature search shows that small steps have been under-
taken in combining ultrasound techniques and that these 
have led to improved results. Larger (multicentre) trials with 
standardized imaging protocols and reporting are necessary 
to reduce user dependency and get more accurate estimates 
of the sensitivity and specificity of the individual ultrasound 
modalities. A standardized reporting system for ultrasound 
modalities is therefore urgently needed. Subsequently, 
refined methods of combining the modalities need to be 
developed and validated. In order to validate the mpUS as 
a whole or any of the modalities involved, a reliable method 
of correlating histopathology to imaging is needed. Meth-
odological challenges including mismatch between imag-
ing and pathology have complicated research and contrib-
uted greatly to the varying results on both the MRI and 
ultrasound platforms. Authors have tried to compensate for 
mismatch between histopathology and imaging, but one can 
never be certain whether over- or under-compensation arises 
[56, 57]. Turkbey et al. [58] devised a method using pros-
tate-specific 3D-printed molds to eliminate plane angulation 
problems. 3D registration of histopathology and imaging as 
proposed by Mischi et al. [59] also corrects for plane mis-
match and could accommodate multiple imaging modalities 
to be mapped with histopathology.
Although mpMRI results from expert centres are encour-
aging, these results vary widely and could not be confirmed 
in clinical practice yet. Further research is needed to finally 
establish consistency [56, 58]. In addition, the mpMRI’s 
PI-RADS system that is used widely has not been validated 
in multicentre studies as suggested in the original article by 
the authors. Because of the influence of methodology on 
results, the only reliable way to compare the performance 
of ultrasound techniques with each other or with mpMRI 
is to perform both in the same study on the same patient 
cohort. Yet unpublished results from our own institution 
showed that DCE-US performed equal to mpMRI in such 
a direct comparison. Several other factors are important in 
the debate around the positioning of MRI and ultrasound 
in clinical practice. The widespread usage of mpMRI is 
prevented by issues of availability, costs and technical chal-
lenges associated with taking biopsies in high magnetic 
fields [60]. For now, in most centres, mpMRI is reserved 
for selected patients with repeated prior negative biop-
sies and persistent clinical suspicion for malignancy [1]. 
Ultrasound-based imaging shares with MRI the advantage 
of not using ionizing radiation; therefore, repeated imag-
ing can be performed without harming the patient. Major 
advantages of ultrasound over MRI are a wider availability, 
reduced cost and time consumption, and the fact that it can 
be performed by the urologist, in the office setting or at the 
bedside.
Conclusion
Important advances have been made in the development of 
ultrasound-based imaging modalities. The latest clinical 
results achieved using these techniques achieve excellent 
results that need to be matched by other modalities. Data 
from recent advances in the form of contrast-compatible 
4D transrectal probes and quantification techniques for 
GSU, C-TRUS, DCE-US and SWE are expected to show 
improved results in the near future. By effectively com-
bining these ultrasound techniques, all targeting different 
properties of malignant tissue, a valuable clinical tool with 
all the advantages of ultrasound could be constructed. The 
literature shows that combining ultrasound modalities in a 
crude fashion can already improve sensitivity by 13–59 %. 
To unlock the full potential of mpUS, standardized imag-
ing protocols and an optimal algorithm for combining the 
imaging results should be developed and validated. No 
research to date integrates the ultrasound modalities in such 
a way.
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